Regression of left ventricular hypertrophy in hypertensive heart transplant recipients treated with enalapril, furosemide, and verapamil.
- 1 August 1991
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 84 (2) , 583-593
- https://doi.org/10.1161/01.cir.84.2.583
Abstract
BACKGROUND This prospective study was designed to examine whether left ventricular (LV) hypertrophy of the denervated transplanted heart may be reversed by medical therapy and, if so, to investigate the time course of this process and its effect on exercise capacity, myocardial function, and cardiac hemodynamics. METHODS AND RESULTS Ten hypertensive heart transplant recipients with LV hypertrophy were evaluated before therapy with enalapril plus furosemide alone or combined with verapamil, at initial blood pressure (BP) control and after 3, 6, 9, and 12 months, using 24-hour noninvasive ambulatory BP monitoring, M-mode and two-dimensional echocardiography, and supine bicycle ergometry. Average 24-hour systolic and diastolic BP declined from 158 +/- 10 and 104 +/- 7 mm Hg to 129 +/- 9 and 84 +/- 10 mm Hg at initial BP control (p less than 0.005 and p less than 0.025, respectively) and total peripheral resistance from 1,687 +/- 177 to 1,376 +/- 122 dyne.sec.cm-5 (p less than 0.025), remaining normal thereafter. Exercise capacity remained unchanged during the study. LV mass, mass-to-volume ratio, and end-diastolic septal plus posterior wall thickness decreased progressively from 211 +/- 30 g, 2.49 +/- 0.62 g/ml, and 25.7 +/- 2.6 mm to 184 +/- 26 g, 2.22 +/- 0.46 g/ml, and 22.5 +/- 1.9 mm after 3 months (all p less than 0.025) and to 174 +/- 25 g, 2.07 +/- 0.38 g/ml, and 21.5 +/- 1.5 mm after 6 months (all p less than 0.005), remaining unaltered at 9 and 12 months. A correlation was found between the decrease in average 24-hour mean BP and LV mass after 3 months of antihypertensive therapy (r = 0.71, p less than 0.05). Systolic meridional wall stress, LV end-diastolic and stroke volume, ejection fraction, and cardiac output remained unchanged throughout the observation period. CONCLUSIONS The results indicate that regression of LV hypertrophy is induced by effective antihypertensive therapy in the denervated transplanted heart. The extent of decrease in average 24-hour BP appears to be the main determinant for the extent of reduction in LV mass. LV afterload as characterized by systolic meridional wall stress, LV size and pump function, and physical exercise capacity of the transplant patients are not influenced by the therapeutic regimen chosen in this study.Keywords
This publication has 29 references indexed in Scilit:
- Prognostic Implications of Echocardiographically Determined Left Ventricular Mass in the Framingham Heart StudyNew England Journal of Medicine, 1990
- The Effects of Antihypertensive Therapy on Left Ventricular Mass in Elderly PatientsNew England Journal of Medicine, 1990
- Ventricular performance in spontaneously hypertensive rats (SHR) with reduced cardiac massCardiovascular Drugs and Therapy, 1989
- Converting-Enzyme Inhibitors in the Treatment of HypertensionNew England Journal of Medicine, 1988
- Einfluß von Enalapril, Furosemid und Verapamil auf die Ciclosporin-Konzentration im VollblutJournal of Molecular Medicine, 1988
- Validation of in vivo two-dimensional echocardiographic dimension measurements using myocardial mass estimates in dogsAmerican Heart Journal, 1987
- The contrasting effects of cyclosporin-A and azathioprine on arterial blood pressure and renal function following cardiac transplantationInternational Journal of Cardiology, 1986
- Cyclosporine-Associated Chronic NephropathyNew England Journal of Medicine, 1984
- Regression of left ventricular hypertrophy from systemic hypertension by enalaprilThe American Journal of Cardiology, 1984
- Cross-sectional echocardiography. II. Analysis of mathematic models for quantifying volume of the formalin-fixed left ventricle.Circulation, 1980